- Home
- WSC vs BLCO Comparison
WSC vs BLCO Comparison
Compare WSC & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WSC
- BLCO
- Stock Information
- Founded
- WSC N/A
- BLCO 1853
- Country
- WSC United States
- BLCO Canada
- Employees
- WSC N/A
- BLCO N/A
- Industry
- WSC Misc Corporate Leasing Services
- BLCO Ophthalmic Goods
- Sector
- WSC Industrials
- BLCO Health Care
- Exchange
- WSC Nasdaq
- BLCO Nasdaq
- Market Cap
- WSC 7.2B
- BLCO 6.3B
- IPO Year
- WSC N/A
- BLCO 2022
- Fundamental
- Price
- WSC $38.57
- BLCO $17.17
- Analyst Decision
- WSC Buy
- BLCO Buy
- Analyst Count
- WSC 10
- BLCO 12
- Target Price
- WSC $45.50
- BLCO $20.73
- AVG Volume (30 Days)
- WSC 1.9M
- BLCO 396.1K
- Earning Date
- WSC 02-18-2025
- BLCO 02-19-2025
- Dividend Yield
- WSC N/A
- BLCO N/A
- EPS Growth
- WSC N/A
- BLCO N/A
- EPS
- WSC 0.13
- BLCO N/A
- Revenue
- WSC $2,405,579,000.00
- BLCO $4,684,000,000.00
- Revenue This Year
- WSC $2.67
- BLCO $17.32
- Revenue Next Year
- WSC $2.80
- BLCO $5.98
- P/E Ratio
- WSC $295.48
- BLCO N/A
- Revenue Growth
- WSC 2.67
- BLCO 18.01
- 52 Week Low
- WSC $32.57
- BLCO $13.16
- 52 Week High
- WSC $52.16
- BLCO $21.69
- Technical
- Relative Strength Index (RSI)
- WSC 68.75
- BLCO 35.11
- Support Level
- WSC $34.34
- BLCO $17.00
- Resistance Level
- WSC $35.70
- BLCO $17.57
- Average True Range (ATR)
- WSC 0.97
- BLCO 0.45
- MACD
- WSC 0.55
- BLCO -0.00
- Stochastic Oscillator
- WSC 89.36
- BLCO 22.80
About WSC WillScot Mobile Mini Holdings Corp.
WillScot Holdings Corp designs, delivers, and services onsite, on-demand space solutions for clients. The company offers turnkey solutions in construction, education, manufacturing, retail, healthcare, and entertainment sectors. The products of the company includes modular office complexes, mobile offices, portable storage containers, and others.
About BLCO Bausch + Lomb Corporation
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.